The consensus price target for Xeris Biopharma’s stock has been on an upward trend, indicating analyst optimism.
Craig-Hallum has set a higher price target of $6.5 for Xeris Biopharma, suggesting potential for significant stock appreciation.
Xeris Biopharma reported a 25% increase in total product sales in the first quarter, driven by Gvoke and Recorlev.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a biopharmaceutical company that focuses on developing therapies in endocrinology, neurology, and gastroenterology. The company markets products like Gvoke, Keveyis, and Recorlev, and is expanding its product pipeline using its proprietary XeriSol and XeriJect platforms. Xeris competes in a challenging market with other biopharmaceutical companies.
The consensus price target for Xeris Biopharma’s stock has shown an upward trend over the past year. Last year, the average price target was $4, which increased to $5 last quarter and remained steady last month. This optimism among analysts may be due to the company’s progress in its development programs and successful commercialization of its products.
Craig-Hallum has set a higher price target of $6.5 for Xeris Biopharma, as highlighted by Seeking Alpha. This suggests that some analysts see even more potential for the company’s stock. Xeris is currently trading above the Buy Threshold of $2.76 and is nearing a breakout above the $3.25 resistance level, indicating strong market interest.
Xeris Biopharma’s revenue growth is primarily driven by its products Gvoke and Recorlev. In the first quarter, the company reported a 25% increase in total product sales compared to the previous year. CEO Paul Edick attributes this growth to the strong performance of Recorlev and the increasing market share of Gvoke.
Despite not yet reporting a positive EPS, Xeris Biopharma’s projected revenue growth indicates significant upside potential. However, the company faces risks such as intense competition and the potential need for additional funding. Investors should monitor news related to Xeris Biopharma’s earnings reports and product developments, as these could impact the stock’s target price and market performance.
